sizofiran has been researched along with Cancer of Cervix in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (31.58) | 18.7374 |
| 1990's | 13 (68.42) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noda, K; Okamura, K; Yajima, A | 1 |
| Hamazaki, Y; Higashiiwai, H; Kuramoto, M; Okamura, K; Suzuki, M; Yajima, A | 1 |
| Fujisaki, S; Fukuma, K; Katabuchi, H; Miyazaki, K; Mizutani, H; Okamura, H | 1 |
| Goto, S; Kera, J; Sakai, S; Soma, GI; Suma, Y; Takeuchi, S | 1 |
| Adachi, T; Hoshino, T; Suzuki, Y; Takayama, M; Yagishita, M | 1 |
| Kurokawa, T; Tamakuma, S | 1 |
| Hanba, K; Morita, S; Nakano, T; Oka, K | 1 |
| Hasegawa, K; Hasuo, Y; Hatae, M; Honjo, H; Kobashi, Y; Kudo, T; Mizutani, K; Nishimura, R; Noda, K; Ochiai, K; Onishi, Y; Ozaki, M; Sasaki, H; Sato, S; Sugiyama, T; Terashima, Y; Yajima, A; Yakushiji, M; Yamamoto, K; Yamamoto, T | 1 |
| Gorai, I; Minaguchi, H; Yanagibashi, T | 1 |
| Akiya, K; Hashimoto, S; Kasamatsu, T; Noda, K; Ozawa, M; Sekiba, K; Sugimori, H; Takeuchi, S; Tomoda, Y; Yajima, A | 1 |
| Hasumi, K; Masubuchi, K; Shimizu, Y | 1 |
| Chen, JT; Fujimoto, I; Hasumi, K; Masubuchi, K; Shimizu, Y; Teshima, H | 1 |
| Inomata, T; Maeda, T; Nishioka, A; Ogawa, Y; Seguchi, H | 1 |
| Hasegawa, K; Kimura, A; Kinugasa, M; Mizuhira, V; Nishimura, R; Ohtsu, F; Okamura, M; Takeuchi, K | 1 |
| Aida, I; Izumi, A; Sekiguchi, I; Suzuki, M; Tamada, T | 1 |
| Hamazaki, Y; Noda, K; Okamura, K; Yajima, A | 1 |
| Chen, JT; Fujimoto, I; Hamada, T; Hasumi, K; Hirai, Y; Masubuchi, K; Nakayama, K; Shimizu, Y | 1 |
| Chihara, T; Fujiwara, A; Fukuda, T; Goto, S; Ichinohe, K; Jimi, S; Kasamatsu, T; Kawai, N; Okamura, K; Suzuki, M | 2 |
6 trial(s) available for sizofiran and Cancer of Cervix
| Article | Year |
|---|---|
Activated (HLA-DR+) T-lymphocyte subsets in cervical carcinoma and effects of radiotherapy and immunotherapy with sizofiran on cell-mediated immunity and survival.
Topics: CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; HLA-DR Antigens; Humans; Immunotherapy; Lymphocyte Activation; Lymphocyte Count; Middle Aged; Proportional Hazards Models; Prospective Studies; Sizofiran; Survival Rate; T-Lymphocyte Subsets; Uterine Cervical Neoplasms | 1995 |
[Effect of 5'-DFUR used concurrently in radiotherapy and immunotherapy uterine cervical cancer--pilot study. Study of 5'-DFUR for Uterine Cervical Cancer].
Topics: Adjuvants, Immunologic; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Administration Schedule; Female; Floxuridine; Humans; Immunotherapy; Middle Aged; Pilot Projects; Sizofiran; Uterine Cervical Neoplasms | 1998 |
Clinical effect of sizofiran combined with irradiation in cervical cancer patients: a randomized controlled study. Cooperative Study Group on SPG for Gynecological Cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Middle Aged; Sizofiran; Uterine Cervical Neoplasms | 1992 |
Adjuvant immunotherapy: two randomized controlled studies of patients with cervical cancer.
Topics: Biological Products; Clinical Trials as Topic; Female; Glycosaminoglycans; Humans; Neoplasm Staging; Picibanil; Random Allocation; Sizofiran; Uterine Cervical Neoplasms | 1989 |
Clinical evaluation of sizofiran combined with irradiation in patients with cervical cancer. A randomized controlled study; a five-year survival rate.
Topics: Antineoplastic Agents; Combined Modality Therapy; Female; Glycosaminoglycans; Humans; Randomized Controlled Trials as Topic; Sizofiran; Survival Rate; Time Factors; Uterine Cervical Neoplasms | 1989 |
Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer. A randomized controlled study.
Topics: Actuarial Analysis; Aged; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation; Female; Glycosaminoglycans; Humans; Leukocyte Count; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Dosage; Random Allocation; Sizofiran; Uterine Cervical Neoplasms | 1986 |
13 other study(ies) available for sizofiran and Cancer of Cervix
| Article | Year |
|---|---|
Adjuvant immunotherapy for cervical cancer. Two randomized controlled studies using OK-432 or sizofiran.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Immunotherapy; Neoplasm Staging; Picibanil; Randomized Controlled Trials as Topic; Sizofiran; Survival Analysis; Uterine Cervical Neoplasms | 1989 |
[Studies on immunotherapy of uterine cervical cancer by administration of schizophyllan (SPG) (author's transl)].
Topics: Aged; Female; Glycosaminoglycans; Humans; Interferon Inducers; Lymphocyte Activation; Lymphocyte Depletion; Middle Aged; Sizofiran; Uterine Cervical Neoplasms | 1980 |
A case report of recurrent cervical cancer which responded to a combination of biological therapies.
Topics: Adult; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Immunologic Factors; Lentinan; Lymphocytes, Tumor-Infiltrating; Neoplasm Recurrence, Local; Neoplasm Staging; Sizofiran; Tumor Necrosis Factor-alpha; Uterine Cervical Neoplasms | 1994 |
[Induction of M-CSF and G-CSF receptor mRNA in peripheral blood mononuclear cells of gynecological cancer by sizofiran].
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Female; Genital Neoplasms, Female; Humans; Leukocytes, Mononuclear; Ovarian Neoplasms; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; RNA, Messenger; Sizofiran; Uterine Cervical Neoplasms | 1993 |
[Two cases of cancer with bone metastases treated with local therapy].
Topics: Adult; Bone Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Esophageal Neoplasms; Female; Humans; Injections, Intralesional; Male; Middle Aged; Picibanil; Radiotherapy Dosage; Sizofiran; Uterine Cervical Neoplasms | 1993 |
Intratumoral administration of sizofiran activates Langerhans cell and T-cell infiltration in cervical cancer.
Topics: Adjuvants, Immunologic; Carcinoma, Squamous Cell; Female; Humans; Immunotherapy; Langerhans Cells; Lymphocytes, Tumor-Infiltrating; Microscopy, Electron; Sizofiran; T-Lymphocytes; Uterine Cervical Neoplasms | 1996 |
Immunological modulation of lymphocyte subpopulation in cervical cancer tissue by sizofiran and OK-432.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation; Antigens, Differentiation, T-Lymphocyte; Carcinoma, Squamous Cell; CD3 Complex; CD4 Antigens; CD5 Antigens; CD8 Antigens; Female; Humans; Immunity; Immunohistochemistry; Lymphocyte Subsets; Middle Aged; Picibanil; Receptors, Antigen, T-Cell; Receptors, Fc; Receptors, IgG; Sizofiran; Uterine Cervical Neoplasms | 1992 |
Augmenting effect of sizofiran on the immunofunction of regional lymph nodes in cervical cancer.
Topics: Adjuvants, Immunologic; Adult; Antibodies, Monoclonal; Female; HLA-DR Antigens; Humans; Immunohistochemistry; Interleukin-2; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Lymph Nodes; Lymphatic Metastasis; Lymphocytes; Middle Aged; Neoplasm Staging; Pelvis; Sizofiran; Uterine Cervical Neoplasms | 1992 |
[Augmentative effect of sizofiran on the immune functions of regional lymph nodes in patients with cervical cancer].
Topics: Adjuvants, Immunologic; Adult; Aged; Antigens, Neoplasm; Antigens, Surface; Female; Humans; In Vitro Techniques; Lymph Nodes; Middle Aged; Sizofiran; Uterine Cervical Neoplasms | 1991 |
[Improvement in the effects of radiation therapy with BRM].
Topics: Adenocarcinoma; Animals; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Radiotherapy Dosage; Sizofiran; T-Lymphocyte Subsets; Uterine Cervical Neoplasms | 1990 |
[Electron microscopic and immunological studies concerning the effect on the antitumor activity of sizofiran (SPG) combined with radiotherapy for cervical cancer].
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Immunity, Cellular; Macrophages; Microscopy, Electron; Sizofiran; Uterine Cervical Neoplasms | 1990 |
[The study on the immunological effect of sizofilan combined with radiotherapy in patients with uterine cervical cancer].
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Humans; Immunity, Cellular; Immunologic Factors; Killer Cells, Natural; Middle Aged; Sizofiran; Uterine Cervical Neoplasms | 1990 |
Augmentation of immune responses of pelvic lymph node lymphocytes in patients with cervical cancer by sizofiran.
Topics: Cytotoxicity, Immunologic; Female; Glycosaminoglycans; Humans; Interleukin-2; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Lymph Nodes; Lymphocytes; Pelvis; Sizofiran; Uterine Cervical Neoplasms | 1989 |